Data concerning the utility of biomarkers for accurate early HCC detection in cirrhotic patients are lacking. 1.2. Methods: We evaluated 112 consecutive Caucasian cirrhotic patients with (n=28) or without (n=84) concomitant HCC at baseline for serum AFP and plasma fibrinogen like protein-2 (FGL-2) levels. Patients without confirmed HCC at baseline were further followed up every six months with ultrasound and serum AFP levels, according to HCC surveillance program. Imaging as well as histological confirmation of HCC was established in patients with new lesions. Du
Liver Fibrosis: Difficulties in Diagnostic and Treatment: A Review-Crimson Pu...CrimsonGastroenterology
Early discovery of liver fibrosis and cirrhosis is becoming more relevant because of enhanced incidence of hepatocellular carcinoma. There a many underlying factors in developing liver fibrosis (i.e. viral hepatitis, steatohepatitis). Diagnosis of liver fibrosis is difficult; chronic liver failure and less distinct fibrosis stages can be underestimated, when laboratory routine parameters and native ultrasound of the liver are unsuspicious. Liver biopsy is a common element of diagnostic workup in hepatic cirrhosis, alongside clinical examination and abdominal ultrasound, and is the accepted diagnostic gold standard. But there is no unitary system of histological classification used to evaluate the degree of fibrosis, and individual systems are often validated only for individual disease entities. On the other hand liver biopsy is of less tolerance for patients. In the last years serological markers for detecting liver fibrosis were developed with different validity. Various imaging modalities have been proposed as methods for assessing liver fibrosis
by liver stiffness measurement. They are sufficient to approve the suspicious of liver fibrosis and/or to uncover unknown chronic liver failure. Studies showed the clinical usefulness of acoustic radiation force impulse shear wave elasticity imaging (ARFI-SWEI) is efficient as a preventive screening method to uncover fibrosis. The ARFI-SWEI system is integrated in an ultrasound device has a good accuracy and high reproducibility. Therapy of liver fibrosis depends on underlying disease and degree of liver failure. When liver failure can be cured liver fibrosis can regress. Direct antifibrotic drugs are
actually not available but in progress.
This document provides a summary of the November 2014 issue of the UTSW Internal Medicine Journal Watch. It includes summaries of articles on topics such as assessing acid-base disturbances, managing Staphylococcus aureus bacteremia, community acquired pneumonia, predicting hepatocellular carcinoma in hepatitis C patients, and guidelines for prioritizing patients for new hepatitis C treatments. It also reviews articles related to infectious diseases, critical care, nephrology, cardiology, and more.
This study evaluated the safety and efficacy of pegylated interferon alpha-2a (PEG-IFN) monotherapy in 78 hepatitis C virus (HCV) positive hemodialysis patients. An early viral response was seen in 61.5% of patients at 12 weeks. However, only 19.2% had undetectable HCV RNA levels at end of treatment. A sustained viral response was achieved in 14.1% of the initial population. Adherence was poor, with 32% unable to complete the 48-week treatment due to adverse effects. Adverse events were common, occurring in 83% of patients. The incidence of serious adverse events was high at 0.19 per patient-year. The study
Hepatocellular & Pancreatic CarcinomasRHMBONCO
The document discusses hepatocellular carcinoma (HCC) and pancreatic cancer, including their epidemiology, risk factors, screening, diagnosis, staging, and management. For HCC, risk factors include hepatitis and other liver diseases, while targeted therapies such as sorafenib have shown efficacy. Surgical resection can cure early HCC but recurrence is common. For pancreatic cancer, risk increases with age and genetic factors, while surgery offers the only chance for cure if the cancer is resectable.
Background: The precise evaluation of hepatic fi brosis is crucial in the management of Chronic Hepatitis C (CHC). Multiple noninvasive serological scores and devices have been used in the accurate prediction of fibrosis however; early changes in non-invasive
biomarkers of liver fibrosis following antiviral therapy are widely unknown. We aim to evaluate changes of liver stiffness and 6 noninvasive serological fibrosis scores, easy to calculate particularly in poor areas, following sofosbuvir- based treatment.
Methods: This is a cohort study that included 155 CHC Egyptian patients. Transient elastography values were recorded as well
as Aspartate Aminotransferase-To-Platelet Ratio Index (APRI), FIB-4, Lok score, fibrosis index, King Score and fibro Q score were calculated at baseline and 12 weeks post-treatment.
3TC-DTG Dual Therapy and Its Implications in Hepatic Steatosis in People Livi...semualkaira
Hepatic disease is one of the major comorbidities
in people living with HIV. We intended to define the incidence of
NAFLD and to identify any factors which may be associated with
such a condition.
This document discusses non-alcoholic fatty liver disease (NAFLD), which ranges from simple steatosis to non-alcoholic steatohepatitis (NASH) and cirrhosis. It occurs without significant alcohol use or other known causes. Risk factors include obesity, dyslipidemia, and type 2 diabetes. Due to the rise in metabolic syndrome, NAFLD is now the most common cause of chronic liver disease. Genetic and metabolic factors like insulin resistance and inflammation contribute to its development and progression. Liver biopsy is still the gold standard for diagnosis but carries risks, so noninvasive imaging methods are being developed and studied.
Alpha-Fetoprotein and the Early Diagnosis of Hepatocellular CarcinomaJohnJulie1
Hepatocellular carcinoma is the most common primary malignant tumor of the liver. Cirrhosisis associated with its carcinogenesis, so periodic surveillance is necessary. Ultrasonography is currently the most appropriate test for screening hepatocellular carcinoma, and alpha-fetoprotein is the most used biomarker despite its low sensitivity
Liver Fibrosis: Difficulties in Diagnostic and Treatment: A Review-Crimson Pu...CrimsonGastroenterology
Early discovery of liver fibrosis and cirrhosis is becoming more relevant because of enhanced incidence of hepatocellular carcinoma. There a many underlying factors in developing liver fibrosis (i.e. viral hepatitis, steatohepatitis). Diagnosis of liver fibrosis is difficult; chronic liver failure and less distinct fibrosis stages can be underestimated, when laboratory routine parameters and native ultrasound of the liver are unsuspicious. Liver biopsy is a common element of diagnostic workup in hepatic cirrhosis, alongside clinical examination and abdominal ultrasound, and is the accepted diagnostic gold standard. But there is no unitary system of histological classification used to evaluate the degree of fibrosis, and individual systems are often validated only for individual disease entities. On the other hand liver biopsy is of less tolerance for patients. In the last years serological markers for detecting liver fibrosis were developed with different validity. Various imaging modalities have been proposed as methods for assessing liver fibrosis
by liver stiffness measurement. They are sufficient to approve the suspicious of liver fibrosis and/or to uncover unknown chronic liver failure. Studies showed the clinical usefulness of acoustic radiation force impulse shear wave elasticity imaging (ARFI-SWEI) is efficient as a preventive screening method to uncover fibrosis. The ARFI-SWEI system is integrated in an ultrasound device has a good accuracy and high reproducibility. Therapy of liver fibrosis depends on underlying disease and degree of liver failure. When liver failure can be cured liver fibrosis can regress. Direct antifibrotic drugs are
actually not available but in progress.
This document provides a summary of the November 2014 issue of the UTSW Internal Medicine Journal Watch. It includes summaries of articles on topics such as assessing acid-base disturbances, managing Staphylococcus aureus bacteremia, community acquired pneumonia, predicting hepatocellular carcinoma in hepatitis C patients, and guidelines for prioritizing patients for new hepatitis C treatments. It also reviews articles related to infectious diseases, critical care, nephrology, cardiology, and more.
This study evaluated the safety and efficacy of pegylated interferon alpha-2a (PEG-IFN) monotherapy in 78 hepatitis C virus (HCV) positive hemodialysis patients. An early viral response was seen in 61.5% of patients at 12 weeks. However, only 19.2% had undetectable HCV RNA levels at end of treatment. A sustained viral response was achieved in 14.1% of the initial population. Adherence was poor, with 32% unable to complete the 48-week treatment due to adverse effects. Adverse events were common, occurring in 83% of patients. The incidence of serious adverse events was high at 0.19 per patient-year. The study
Hepatocellular & Pancreatic CarcinomasRHMBONCO
The document discusses hepatocellular carcinoma (HCC) and pancreatic cancer, including their epidemiology, risk factors, screening, diagnosis, staging, and management. For HCC, risk factors include hepatitis and other liver diseases, while targeted therapies such as sorafenib have shown efficacy. Surgical resection can cure early HCC but recurrence is common. For pancreatic cancer, risk increases with age and genetic factors, while surgery offers the only chance for cure if the cancer is resectable.
Background: The precise evaluation of hepatic fi brosis is crucial in the management of Chronic Hepatitis C (CHC). Multiple noninvasive serological scores and devices have been used in the accurate prediction of fibrosis however; early changes in non-invasive
biomarkers of liver fibrosis following antiviral therapy are widely unknown. We aim to evaluate changes of liver stiffness and 6 noninvasive serological fibrosis scores, easy to calculate particularly in poor areas, following sofosbuvir- based treatment.
Methods: This is a cohort study that included 155 CHC Egyptian patients. Transient elastography values were recorded as well
as Aspartate Aminotransferase-To-Platelet Ratio Index (APRI), FIB-4, Lok score, fibrosis index, King Score and fibro Q score were calculated at baseline and 12 weeks post-treatment.
3TC-DTG Dual Therapy and Its Implications in Hepatic Steatosis in People Livi...semualkaira
Hepatic disease is one of the major comorbidities
in people living with HIV. We intended to define the incidence of
NAFLD and to identify any factors which may be associated with
such a condition.
This document discusses non-alcoholic fatty liver disease (NAFLD), which ranges from simple steatosis to non-alcoholic steatohepatitis (NASH) and cirrhosis. It occurs without significant alcohol use or other known causes. Risk factors include obesity, dyslipidemia, and type 2 diabetes. Due to the rise in metabolic syndrome, NAFLD is now the most common cause of chronic liver disease. Genetic and metabolic factors like insulin resistance and inflammation contribute to its development and progression. Liver biopsy is still the gold standard for diagnosis but carries risks, so noninvasive imaging methods are being developed and studied.
Alpha-Fetoprotein and the Early Diagnosis of Hepatocellular CarcinomaJohnJulie1
Hepatocellular carcinoma is the most common primary malignant tumor of the liver. Cirrhosisis associated with its carcinogenesis, so periodic surveillance is necessary. Ultrasonography is currently the most appropriate test for screening hepatocellular carcinoma, and alpha-fetoprotein is the most used biomarker despite its low sensitivity
Alpha-Fetoprotein and the Early Diagnosis of Hepatocellular CarcinomaJapaneseJournalofGas
Hepatocellular carcinoma is the most common primary malignant tumor of the liver. Cirrhosisis associated with its carcinogenesis, so periodic surveillance is necessary. Ultrasonography is currently the most appropriate test for screening hepatocellular carcinoma, and alpha-fetoprotein is the most used biomarker despite its low sensitivity
Cirrhosis is a dynamic disease with varying prognosis depending on clinical stage. It results from mechanisms leading to necroinflammation and fibrogenesis. Later stages are characterized by portal hypertension, ascites, encephalopathy, and risk of hepatocellular carcinoma. Treatment and prevention of complications, including screening and cause-specific therapies, can improve outcomes for patients with cirrhosis.
Kumpulan abstrak penelitian hepatologiDesiPurnama2
This document contains 10 abstracts related to hepatology research. The first abstract summarizes a study analyzing quantitative hepatitis B surface antigen (HBsAg) as a predictor of liver fibrosis in hepatitis B patients. The study evaluated the diagnostic value of quantitative HBsAg levels and liver fibrosis assessed by transient elastography. The second abstract examines the correlation between serum vascular endothelial growth factor (VEGF) level, portal vein diameter, portal flow velocity, and the severity of liver cirrhosis based on Child-Turcotte-Pugh score. The third abstract analyzes the correlation between APRI test score and serum hyaluronic acid level with the degree of hepatic fibrosis in hepatitis C patients assessed by transient elastography.
This study aimed to determine the frequency of steatosis in 158 hepatitis C patients and examine its relationship to fibrosis. The key findings were:
1) Steatosis was present in 45% of liver biopsies. A strong correlation was observed between increasing steatosis and worsening fibrosis.
2) No significant relationship was found between steatosis and either BMI or age.
3) The results suggest steatosis may play a role in accelerating liver disease progression in hepatitis C by fueling free radical production, amplifying the virus's cytopathic effect. Efforts to control steatosis may help slow disease progression.
This study examined 158 hepatitis C patients to determine the frequency of liver fat (steatosis) and its relationship to fibrosis severity. The results showed:
1) Steatosis was present in 45% of patients and ranged from mild to severe.
2) A strong correlation was found between increasing steatosis severity and worsening fibrosis stage.
3) No significant relationships were found between steatosis and either patient age or BMI. This suggests steatosis may play a role in accelerating liver disease progression in hepatitis C.
This study examined 158 hepatitis C patients to determine the frequency of liver fat (steatosis) and its relationship to fibrosis severity. The results showed:
1) Steatosis was present in 45% of patients and ranged from mild to severe.
2) A strong correlation was found between increasing steatosis severity and worsening fibrosis stage.
3) No significant relationships were found between steatosis and either patient age or BMI. This suggests steatosis may play a role in accelerating liver disease progression in hepatitis C.
Gemcitabine and Cisplatin In Metastatic Carcinoma Gallbladder. A Single Insti...iosrjce
IOSR Journal of Dental and Medical Sciences is one of the speciality Journal in Dental Science and Medical Science published by International Organization of Scientific Research (IOSR). The Journal publishes papers of the highest scientific merit and widest possible scope work in all areas related to medical and dental science. The Journal welcome review articles, leading medical and clinical research articles, technical notes, case reports and others.
This document summarizes primary and secondary liver malignancies, their management, and principles of liver resection. It covers hepatocellular carcinoma (HCC), the most common primary liver cancer, risk factors, presentation, diagnosis, staging, and treatment options. Intrahepatic cholangiocarcinoma and metastatic tumors to the liver are also discussed. Surgical resection is the main curative treatment for early-stage HCC and intrahepatic cholangiocarcinoma when possible.
This lecture was part of an educational course performed by the IATTGI group this August in Buenos Aires and describes novel targets and novel drugs in hepatocellular carcinoma.
Gastrointestinal Cancer: Research & Therapy is an open access, peer reviewed, scholarly journal dedicated to publish articles covering all areas of Gastrointestinal Cancer.
The journal aims to promote research communications and provide a forum for doctors, researchers, physicians and healthcare professionals to find most recent advances in all areas of Gastrointestinal Cancer. Gastrointestinal Cancer: Research & Therapy accepts original research articles, reviews, mini reviews, case reports and rapid communication covering all aspects of Gastrointestinal Cancer.
Gastrointestinal Cancer: Research & Therapy strongly supports the scientific up gradation and fortification in related scientific research community by enhancing access to peer reviewed scientific literary works. Austin Publishing Group also brings universally peer reviewed journals under one roof thereby promoting knowledge sharing, mutual promotion of multidisciplinary science.
HCC Clinical update and hints from AASLD 2017 guidelines mainly about surveillance, diagnosis and treatment of Hepatocellular carcinoma in different stages.
Risk factors of chronic liver disease amongst patients receiving care in a Ga...iosrjce
IOSR Journal of Dental and Medical Sciences is one of the speciality Journal in Dental Science and Medical Science published by International Organization of Scientific Research (IOSR). The Journal publishes papers of the highest scientific merit and widest possible scope work in all areas related to medical and dental science. The Journal welcome review articles, leading medical and clinical research articles, technical notes, case reports and others.
IRF5 Promotes the Progression of Hepatocellular Carcinoma and is Regulated by...NainaAnon
1. The study found that IRF5 was upregulated in hepatocellular carcinoma (HCC) tissues compared to normal tissues based on mRNA and protein levels.
2. Overexpression of IRF5 promoted the growth and colony formation of HCC cells in vitro, while silencing IRF5 inhibited HCC cell growth and proliferation.
3. TRIM35 was found to interact with and promote the degradation of IRF5. TRIM35 expression was negatively correlated with IRF5 levels in HCC clinical samples.
Trimodal Management of Locally Invasive Urinary Bladder CancerNainaAnon
To evaluate the response of the modern bladder-preservation treatment modality; Trimodal Therapy (TMT) in Muscle-Invasive Bladder Cancer (MIBC). Aiming at bladder preservation in MIBC, TMT was to offer a quality- of-life advantage and avoid potential morbidity and mortality of Radical Cystectomy (RC) without compromising oncologic outcomes.
Alterations of Gut Microbiota From Colorectal Adenoma to CarcinomaNainaAnon
The document analyzes differences in gut microbiota between healthy individuals, those with colorectal adenomas (CRA), and those with colorectal cancer (CRC). 16S rRNA sequencing was performed on tissue samples from 11 individuals in each group. Microbial diversity was lower in CRA patients and higher in CRC patients compared to healthy individuals. The relative abundance of Fusobacteria was lower in CRA and higher in CRC. This suggests alterations in gut microbiota occur from adenoma to carcinoma, with Fusobacteria potentially playing a role in colorectal cancer development.
Prognosis of Invasive Micropapillary Carcinoma of the Breast Analyzed by Usin...NainaAnon
Invasive micropapillary carcinoma (IMPC) is a rare type of breast cancer with high frequency of regional lymph node metastasis. However, the prognosis of IMPC has remained controversial for decades. We aimed to compare the differences of prognosis between IMPC and Invasive ductal carcinoma(IDC) of the breast by utilizing Surveillance, Epidemiology, and End Results (SEER) database.
Uretero-Enteric Anastomosis Stricture after Urinary Diversion; Detailed Analy...NainaAnon
To report the lessons we have learned in the management of uretero-enteric anastomosis stricture (UEAS) in a tertiary urology center over a decade of experience.
Clinic Correlation and Prognostic Value of P4HB and GRP78 Expression in Gastr...NainaAnon
Prolyl 4-hydroxylase, beta polypeptide (P4HB) and Glucose‑regulated protein 78 (GRP78) represent for poor prognosis of various cancers, while rare research investigate correlation of them. This study aimed to explore correlation and prognostic value of them in gastric cancer (GC).
Combined Analysis of Micro RNA and Proteomic Profiles and Interactions in Pat...NainaAnon
The Liquid Mass System(LMS) includes an Easy nLC1000 (Thermo Fisher) coupled ultra-high resolution mass spectrometer Orbitrap Fusion Lumos (Thermo Fisher) with a Thermo Fisher electrospray source. Each injection is sent to a preset column (Acclaim PepMap C18, 100 μm x 2 cm, Thermo Scientific) for adsorption at a flow rate of 3 L/min. The sample is then sent to the analyzer column (Acclaim PepMap C18, 75 μm x 15 cm, Thermo Scientific) for separation
Skeletal muscle channelopathy are rare heterogeneous episodic disorders with marked genotypic and phenotypic variability resulting in periodic paralysis, and falls in young people which often misdiagnosed or undiagnosed due to its rarity, often the symptoms are miscommunicated to the treating phycision due to its episodic nature and not uncommonly physical examination by the time patient attend the clinic or hospital will be unremarkable apart from periodic muscle paralysis where patient will presented to ED with flaccid weakness,
The Use of the Infrared Laser Therapy of 890-910 NM for the Treatment Breast ...NainaAnon
The document summarizes experimental and clinical research on using infrared laser therapy between 890-910 nm to treat breast cancer. Experimental studies showed laser therapy inhibited tumor growth in mice and rats, with the most effective dose being 0.46 J/cm2. Clinical studies involved 136 patients with breast cancer divided into 3 groups: those receiving laser therapy before surgery, after surgery, or as the sole treatment. Laser therapy reduced postoperative complications, improved immune function and quality of life, and increased survival time. Histological analysis found over 50% of tumor tissue disappeared due to necrosis and fibrosis with effective laser treatment regimens.
More Related Content
Similar to Predictive Value of Biomarkers Fibrinogen Like Protein-2 and A-Fetoprotein for Hepatocellular Carcinoma Among Patients with Liver Cirrhosis
Alpha-Fetoprotein and the Early Diagnosis of Hepatocellular CarcinomaJapaneseJournalofGas
Hepatocellular carcinoma is the most common primary malignant tumor of the liver. Cirrhosisis associated with its carcinogenesis, so periodic surveillance is necessary. Ultrasonography is currently the most appropriate test for screening hepatocellular carcinoma, and alpha-fetoprotein is the most used biomarker despite its low sensitivity
Cirrhosis is a dynamic disease with varying prognosis depending on clinical stage. It results from mechanisms leading to necroinflammation and fibrogenesis. Later stages are characterized by portal hypertension, ascites, encephalopathy, and risk of hepatocellular carcinoma. Treatment and prevention of complications, including screening and cause-specific therapies, can improve outcomes for patients with cirrhosis.
Kumpulan abstrak penelitian hepatologiDesiPurnama2
This document contains 10 abstracts related to hepatology research. The first abstract summarizes a study analyzing quantitative hepatitis B surface antigen (HBsAg) as a predictor of liver fibrosis in hepatitis B patients. The study evaluated the diagnostic value of quantitative HBsAg levels and liver fibrosis assessed by transient elastography. The second abstract examines the correlation between serum vascular endothelial growth factor (VEGF) level, portal vein diameter, portal flow velocity, and the severity of liver cirrhosis based on Child-Turcotte-Pugh score. The third abstract analyzes the correlation between APRI test score and serum hyaluronic acid level with the degree of hepatic fibrosis in hepatitis C patients assessed by transient elastography.
This study aimed to determine the frequency of steatosis in 158 hepatitis C patients and examine its relationship to fibrosis. The key findings were:
1) Steatosis was present in 45% of liver biopsies. A strong correlation was observed between increasing steatosis and worsening fibrosis.
2) No significant relationship was found between steatosis and either BMI or age.
3) The results suggest steatosis may play a role in accelerating liver disease progression in hepatitis C by fueling free radical production, amplifying the virus's cytopathic effect. Efforts to control steatosis may help slow disease progression.
This study examined 158 hepatitis C patients to determine the frequency of liver fat (steatosis) and its relationship to fibrosis severity. The results showed:
1) Steatosis was present in 45% of patients and ranged from mild to severe.
2) A strong correlation was found between increasing steatosis severity and worsening fibrosis stage.
3) No significant relationships were found between steatosis and either patient age or BMI. This suggests steatosis may play a role in accelerating liver disease progression in hepatitis C.
This study examined 158 hepatitis C patients to determine the frequency of liver fat (steatosis) and its relationship to fibrosis severity. The results showed:
1) Steatosis was present in 45% of patients and ranged from mild to severe.
2) A strong correlation was found between increasing steatosis severity and worsening fibrosis stage.
3) No significant relationships were found between steatosis and either patient age or BMI. This suggests steatosis may play a role in accelerating liver disease progression in hepatitis C.
Gemcitabine and Cisplatin In Metastatic Carcinoma Gallbladder. A Single Insti...iosrjce
IOSR Journal of Dental and Medical Sciences is one of the speciality Journal in Dental Science and Medical Science published by International Organization of Scientific Research (IOSR). The Journal publishes papers of the highest scientific merit and widest possible scope work in all areas related to medical and dental science. The Journal welcome review articles, leading medical and clinical research articles, technical notes, case reports and others.
This document summarizes primary and secondary liver malignancies, their management, and principles of liver resection. It covers hepatocellular carcinoma (HCC), the most common primary liver cancer, risk factors, presentation, diagnosis, staging, and treatment options. Intrahepatic cholangiocarcinoma and metastatic tumors to the liver are also discussed. Surgical resection is the main curative treatment for early-stage HCC and intrahepatic cholangiocarcinoma when possible.
This lecture was part of an educational course performed by the IATTGI group this August in Buenos Aires and describes novel targets and novel drugs in hepatocellular carcinoma.
Gastrointestinal Cancer: Research & Therapy is an open access, peer reviewed, scholarly journal dedicated to publish articles covering all areas of Gastrointestinal Cancer.
The journal aims to promote research communications and provide a forum for doctors, researchers, physicians and healthcare professionals to find most recent advances in all areas of Gastrointestinal Cancer. Gastrointestinal Cancer: Research & Therapy accepts original research articles, reviews, mini reviews, case reports and rapid communication covering all aspects of Gastrointestinal Cancer.
Gastrointestinal Cancer: Research & Therapy strongly supports the scientific up gradation and fortification in related scientific research community by enhancing access to peer reviewed scientific literary works. Austin Publishing Group also brings universally peer reviewed journals under one roof thereby promoting knowledge sharing, mutual promotion of multidisciplinary science.
HCC Clinical update and hints from AASLD 2017 guidelines mainly about surveillance, diagnosis and treatment of Hepatocellular carcinoma in different stages.
Risk factors of chronic liver disease amongst patients receiving care in a Ga...iosrjce
IOSR Journal of Dental and Medical Sciences is one of the speciality Journal in Dental Science and Medical Science published by International Organization of Scientific Research (IOSR). The Journal publishes papers of the highest scientific merit and widest possible scope work in all areas related to medical and dental science. The Journal welcome review articles, leading medical and clinical research articles, technical notes, case reports and others.
Similar to Predictive Value of Biomarkers Fibrinogen Like Protein-2 and A-Fetoprotein for Hepatocellular Carcinoma Among Patients with Liver Cirrhosis (12)
IRF5 Promotes the Progression of Hepatocellular Carcinoma and is Regulated by...NainaAnon
1. The study found that IRF5 was upregulated in hepatocellular carcinoma (HCC) tissues compared to normal tissues based on mRNA and protein levels.
2. Overexpression of IRF5 promoted the growth and colony formation of HCC cells in vitro, while silencing IRF5 inhibited HCC cell growth and proliferation.
3. TRIM35 was found to interact with and promote the degradation of IRF5. TRIM35 expression was negatively correlated with IRF5 levels in HCC clinical samples.
Trimodal Management of Locally Invasive Urinary Bladder CancerNainaAnon
To evaluate the response of the modern bladder-preservation treatment modality; Trimodal Therapy (TMT) in Muscle-Invasive Bladder Cancer (MIBC). Aiming at bladder preservation in MIBC, TMT was to offer a quality- of-life advantage and avoid potential morbidity and mortality of Radical Cystectomy (RC) without compromising oncologic outcomes.
Alterations of Gut Microbiota From Colorectal Adenoma to CarcinomaNainaAnon
The document analyzes differences in gut microbiota between healthy individuals, those with colorectal adenomas (CRA), and those with colorectal cancer (CRC). 16S rRNA sequencing was performed on tissue samples from 11 individuals in each group. Microbial diversity was lower in CRA patients and higher in CRC patients compared to healthy individuals. The relative abundance of Fusobacteria was lower in CRA and higher in CRC. This suggests alterations in gut microbiota occur from adenoma to carcinoma, with Fusobacteria potentially playing a role in colorectal cancer development.
Prognosis of Invasive Micropapillary Carcinoma of the Breast Analyzed by Usin...NainaAnon
Invasive micropapillary carcinoma (IMPC) is a rare type of breast cancer with high frequency of regional lymph node metastasis. However, the prognosis of IMPC has remained controversial for decades. We aimed to compare the differences of prognosis between IMPC and Invasive ductal carcinoma(IDC) of the breast by utilizing Surveillance, Epidemiology, and End Results (SEER) database.
Uretero-Enteric Anastomosis Stricture after Urinary Diversion; Detailed Analy...NainaAnon
To report the lessons we have learned in the management of uretero-enteric anastomosis stricture (UEAS) in a tertiary urology center over a decade of experience.
Clinic Correlation and Prognostic Value of P4HB and GRP78 Expression in Gastr...NainaAnon
Prolyl 4-hydroxylase, beta polypeptide (P4HB) and Glucose‑regulated protein 78 (GRP78) represent for poor prognosis of various cancers, while rare research investigate correlation of them. This study aimed to explore correlation and prognostic value of them in gastric cancer (GC).
Combined Analysis of Micro RNA and Proteomic Profiles and Interactions in Pat...NainaAnon
The Liquid Mass System(LMS) includes an Easy nLC1000 (Thermo Fisher) coupled ultra-high resolution mass spectrometer Orbitrap Fusion Lumos (Thermo Fisher) with a Thermo Fisher electrospray source. Each injection is sent to a preset column (Acclaim PepMap C18, 100 μm x 2 cm, Thermo Scientific) for adsorption at a flow rate of 3 L/min. The sample is then sent to the analyzer column (Acclaim PepMap C18, 75 μm x 15 cm, Thermo Scientific) for separation
Skeletal muscle channelopathy are rare heterogeneous episodic disorders with marked genotypic and phenotypic variability resulting in periodic paralysis, and falls in young people which often misdiagnosed or undiagnosed due to its rarity, often the symptoms are miscommunicated to the treating phycision due to its episodic nature and not uncommonly physical examination by the time patient attend the clinic or hospital will be unremarkable apart from periodic muscle paralysis where patient will presented to ED with flaccid weakness,
The Use of the Infrared Laser Therapy of 890-910 NM for the Treatment Breast ...NainaAnon
The document summarizes experimental and clinical research on using infrared laser therapy between 890-910 nm to treat breast cancer. Experimental studies showed laser therapy inhibited tumor growth in mice and rats, with the most effective dose being 0.46 J/cm2. Clinical studies involved 136 patients with breast cancer divided into 3 groups: those receiving laser therapy before surgery, after surgery, or as the sole treatment. Laser therapy reduced postoperative complications, improved immune function and quality of life, and increased survival time. Histological analysis found over 50% of tumor tissue disappeared due to necrosis and fibrosis with effective laser treatment regimens.
The Use of the Infrared Laser Therapy of 890-910 NM for the Treatment Breast ...NainaAnon
The experimental studies were conducted with Walker's carcinosarcoma n256 (from the U.S.A. bank), cancer of the mammary gland (RMK-1). Spontaneous –mice with mammary glands cancer (type B). The tasks were as follows: to study the effect of different doses LLLT on the growth of experimental tumors. Evaluation of the effectiveness by applying LLLT in combination with various chemotherapeutic agents (vincristin, 5-Fu, ciclophosphan). Research of LLLR effect on different types of tumors show that this treatment can be used for tumors-statistic effect and for increasing life-span in animals. Applying LLLR in combination with chemotherapeutic agents causes tumors-static action. The most effective combination was LLLT + vincristin which caused the inhibition of tumor growth in Walker's carcinosarcoma-by 92,87%, in RMK-1 - by 90,29% in comparing to controls. The combination of LLLT with HpD showed - the effect of laser therapy takes place in 30 min before the irradiation and is accompanied by a sharp reduction of the preparation's accumulation in the tumor cells.
Prevalence of Hpv Infection in the Lekoumou and Niari Departments (Congo Braz...NainaAnon
This study aimed to determine the prevalence of HPV infection in women in the Lekoumou and Niari departments of Congo Brazzaville. The researchers collected samples from 100 women aged 16-73 and tested them for HPV. They found an overall HPV prevalence of 29%, with the highest rates (58.3%) in women over 50. No significant associations were found between HPV infection and factors like education level, age of first intercourse, number of sexual partners, or number of pregnancies. The study provides baseline data on HPV prevalence in these regions of Congo to help guide cervical cancer prevention efforts.
Upper Rectal Cancer: Benefit After Preoperative Chemoradiation Versus Upfront...NainaAnon
Upper rectal cancer management is controversial. The present series reports the outcomes of treatment comparing neoadjuvant chemoradiation (NCRT) versus upfront surgery.
Follow-Up Strategies in Focal Liver Lesions And Treatment MethodsNainaAnon
Today, advances in cross-sectional imaging have led to the detection and early recognition of incidental/focal liver lesions (FCL). In approximately 17,000 cases of chest CT, incidental liver lesions were found in 6% [1]. In general, FCL consists of hepatocytes, biliary epithelium, mesenchymal tissue, connective tissue, or metastasized cells from distant sites. Most incidental lesions are benign, some may require careful management and treatment.
Pancreatic Adenocarcinoma with Isolated Venous Involvement: Is Neoadjuvant Tr...NainaAnon
Neoadjuvant Treatment (NAT) is indicated in locally advanced tumors and improves the results of subsequent surgery. In borderline tumors, the place of this preoperative treatment is more controversial, probably because borderline tumors are a heterogeneous group. We focused on the tumors with venous involvement without any arterial involvement and studied the results of neoadjuvant treatment in this particular group.
The Black Fungus is One of the Bad Consequences of COVID 19NainaAnon
Recently, since the emergence of the Covid 19 pandemic, the whole world has been waiting for what comes after Corona and when that pandemic will disappear and how to get rid of it. Therefore, all countries, whether Arab or foreign, sought to empty scientific research to produce a vaccine to treat this pandemic. These circumstances have inflicted material and human losses for all countries. In an attempt to combat Covid 19 after the vaccine was manufactured, however, the winds are coming in what ships do not desire, so there is a new outbreak, namely the black fungus.
Circulating Tumor Cells and Cell-Free Nucleic Acids as Predictor Factors for ...NainaAnon
Pancreatic cancer remains as one of the most aggressive and deadliest of cancers largely due to formidable challenges in diagnosis and therapy. Consensus standard treatment for patients with nonmetastatic Pancreatic Cancer (PC) incorporates possible neoadjuvant chemotherapy with timely surgical resection and adjuvant chemotherapy. However, despite all the sophistication of modern radiological and endoscopic techniques, the decision regarding operability is often only made intra-operatively, therefore subjecting a patient to unnecessary surgical intervention, and postponing the possibility of starting early chemotherapy.
Research Progress in Chronic Lymphocytic LeukemiaNainaAnon
Cancer is an uncontrolled division of cell occurs due to genetic alterations and mutation. Chronic lymphocytic leukemia is the heterogeneous lymphocytic malignancy worldwide that leads to death. The advancement of genetic analysis techniques and the identification of suitable biomarkers show significant differences in the treatment period. In this paper will discuss the microRNA that is small Non-coding RNAs and is involved in CLL beginning, development, and resistance to therapy and also will explain the stages of CLL.
Genetics of Breast and Ovary Cancers Associated with Hereditary Cancers and t...NainaAnon
Carriers of the BRCA-1/2 mutation have increased and variable risks of Breast Cancer (BC) and ovarian cancer and vary or are modified by common genetic variants and their incidence genetic testing and risk-reducing surgery has increased, they should receive advice and evaluation by the physician with experience in genetics.
Increased of Protein O-Fucosyl Transferase 1 and 2 Genes Expression in Gastri...NainaAnon
Gastric cancer is one of the most common cancers in the world. Gastric cancer usually occurs at an advanced age (average ≥ 65 years) and has symptoms similar to gastric ulcers and other gastric infections, its early diagnosis is one of the major problems of this type of cancer. Molecular mechanisms initiate cancer and the molecular changes of normal cells compared to cancer cells are very important. dysfunction of Fucosyl transferase enzymes is associated with gastric cancer.
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
2. clinicsofoncology.com 2
Volume 5 Issue 3 -2021 Research Article
etiology (chronic viral hepatitis, alcoholic liver disease, metabolic
disturbances, autoimmune liver diseases etc.) represents an im-
portant risk factor for HCC as all etiologic forms of cirrhosis may
be complicated by tumor formation [3].
Long-term follow-up studies have found that approximately 1–8%
of patients with liver cirrhosis develop HCC per year, especially
those with features of severe liver disease and/or significant portal
hypertension [3]. Patients at high risk of developing HCC, such as
cirrhotics, should be entered into surveillance programs in order to
find HCC at early stages in which potentially curative treatments
are feasible. Liver ultrasound every six months, with or without
concomitant use of serum a-fetoprotein (AFP) levels, is strongly
recommended by EASL/AASLD/APASL guidelines for all cir-
rhotic patients participating in HCC surveillance programs [3, 4,
5]. Data concerning the utility of several proposed tumor biomark-
ers for accurate early HCC detection are still lacking.
Tumor microenvironment is the major site for tumor cell prolifer-
ation and differentiation that significantly affects carcinogene-
sis, vascular invasion/metastasis and response to therapy [6]. The
HCC tumor microenvironment is divided into cellular (liver sinu-
soidal endothelial cells, hepatic stellate cells etc) and non-cellular
components. Moreover, infiltrating immune cells are present in
HCC (neutrophils, lymphocytes, tumor-associated macrophages,
dendritic cells, myeloid-derived suppressor cells), creating a
unique microenvironment that determines tumor growth as well
as prognosis and response to immunotherapy [7]. Fibrinogen-like
protein 2 (FGL-2) is a member of the fibrinogen-like protein fam-
ily that holds a central role in both innate and adaptive immunity.
Soluble fibrinogen-like protein 2 (sFGL-2) is the soluble form of
fibrinogen-like protein 2, that is mainly secreted by regulatory T
cell (Treg) populations and creates a potently immunosuppres-
sive microenvironment, so sFGL-2 might play a role in inhibit-
ing endogenous antitumor immune responses [8]. A recent study
suggests that FGL-2 may promote the growth of hepatocellular
carcinoma by promoting the accumulation of myeloid-derived
suppressor cells in the tumor microenvironment [9].
Data concerning soluble FGL-2 levels in patients with chronic
hepatitis B [10], chronic hepatitis C [8], liver cirrhosis and HCC
[11] suggest that there is a significant correlation between them
and the progression and severity of underlying liver disease as
well as with the clinical outcome. A study in cirrhotic patients with
HCC concluded that sFGL-2 protein is a novel effector molecule
of activated hepatic stellate cells, which suppresses CD8 T cell
proliferation and interferon-gamma production and it subsequent-
ly might contribute to immune suppression during liver fibrosis
and carcinogenesis [11]. To our knowledge the role of soluble
FGL-2 levels in the prediction of hepatocellular carcinoma among
cirrhotic patients under HCC surveillance program has not been
investigated yet.
The aim of our study was to evaluate the predictive value of the
biomarkers AFP and FGL-2 in the appearance of HCC among
Caucasian cirrhotic patients of various etiologies who were fol-
lowed-up according to an HCC surveillance program.
3. Materials & Methods
3.1. Patients: We prospectively evaluated serum FGL-2 levels of
consecutive compensated or decompensated Caucasian cirrhotic
patients with or without concomitant HCC presenting in the outpa-
tient Hepatology Unit of General and Oncology Hospital of Kifisia
‘‘Agioi Anargyroi”. Patient inclusion commenced in September
2014 and ended in January 2015. All patients included had histo-
ry of chronic liver disease of various etiologies and diagnosis of
compensated (confirmed by either liver biopsy or transient elas-
tography) or decompensated liver cirrhosis. All cirrhotic patients
with chronic HCV infection participated in the study had received
antiviral treatment in the past and exhibited sustained virological
response (undetectable serum HCV-RNA twelve weeks follow-
ing treatment cessation and at least once annually). Moreover, all
HBV-related cirrhotic patients participated were appropriately vi-
rologically suppressed (undetectable serum HBV-DNA levels us-
ing a sensitive PCR assay with a cut-off of 13 IU/ml at least once
annually) with long term nucleos(t)ide analogues therapy (ente-
cavir or tenofovir). Cirrhotic patients of any etiology who declare
current alcohol use were also excluded.
Decompensated liver cirrhosis was defined by a history of at least
one major cirrhosis-related complication, such as portal hyperten-
sion related bleeding, hepatic encephalopathy, ascites with Serum
AscitesAlbumin Gradient (SAAG) >1.1 g/dL or jaundice.Absence
of bacterial infection was based on clinical examination, absence of
findings on chest X-ray suggestive of lower respiratory tract infec-
tions and negativity of blood, urine and ascitic fluid cultures. The
neutrophil count in ascitic fluid (<250/mm³) was also evaluated to
exclude spontaneous bacterial peritonitis in cirrhotic patients with
ascites. For the baseline characteristics of the study population,
demographic data were collected through medical history, while
hematological and biochemical tests were performed using stan-
dard laboratory methods. For the assessment of severity of chron-
ic liver disease, well defined scores for cirrhotic patients, such as
Child-Pugh (CP) and MELD, were used. Contrast enhanced CT or
MRI were available, within the last 6 months prior to the baseline
visit, in all the included patients in order to suspect or to exclude
cirrhotic patients with concurrent HCC. Histological confirmation
of HCC was done in all patients with suspected lesions at baseline
evaluation. Patients with HCC were further staged according to the
Barcelona Clinic Liver Cancer (BCLC) staging system.
Cirrhotic patients without confirmed HCC at baseline were further
followed up every six months with liver ultrasound and serum a-fe-
toprotein levels, according to the HCC surveillance program that
is used in our Department. Patients with new lesions suggestive
3. Volume 5 Issue 3 -2021 Research Article
clinicsofoncology.com 3
of HCC during the surveillance program were further evaluated
with contrast enhanced CT or MRI and histological confirmation
of HCC was established with imaging guided biopsy of the lesion.
Written informed consent was collected from all patients partici-
pating in the current study. The study protocol was in accordance
with the Declaration of Helsinki and was evaluated and approved
by the Ethics Committee of the School of Health Sciences of the
National and Kapodistrian University of Athens, Greece.
3.2. Collection of Samples and Measurements: Collection of
samples was performed when the patients presented in the out-
patient Hepatology Unit, at the same time as demographical data
were recorded and routine laboratory tests were ordered. Whole
blood (approximately 10ml) was collected from peripheral veins
of patients and serum as well as plasma was immediately separated
and stored frozen at -80o C until further analysis. Soluble FGL-2
levels were measured from plasma samples using a commercial-
ly available ELISA kit (Cloud-Clone Corp, Houston, TX 77084,
USA) following the specific instructions of the manufacturer.
3.3. Statistical Analysis: Continuous variables are presented as
mean (standard deviation) or median (range), while categorical
variables are presented as numbers (percentages).
We used the Kolmogorov-Smirnov test (p>0.05 for all variables)
and normal Q-Q plots to test the normality assumption. Univar-
iate analysis between demographic and clinical data and HCC
appearance included chi-square test, chi-square trend test and
independent samples t-test. Also, the relation between biomark-
ers and HCC appearance was assessed with Mann-Whitney test
since biomarkers did not follow normal distribution. We applied
multivariate logistic regression analysis with HCC appearance
as the dependent variable to eliminate cofounding. In that case,
we estimated odds ratios, 95% confidence intervals and p-values.
P-values of less than 0.05 were considered significant. Statistical
analysis was performed with the Statistical Package for Social Sci-
ences software (IBM Corp. Released 2012. IBM SPSS Statistics
for Windows, Version 21.0. Armonk, NY: IBM Corp.)
4. Results
Between September 2014 and January 2015, 112 consecutive
Caucasian cirrhotic patients (81 males) presenting in the outpa-
tient Hepatology Unit of General and Oncology Hospital of Kifisia
‘‘Agioi Anargyroi” were evaluated. Sixty-eight of them (60.7%)
were categorized at CP-A score and 44 (39.3%) at CP-B/C score
whereas the median CP score of the whole population was 6 and
the median MELD score was 9. Twenty-eight out of 112 cirrhot-
ic patients (25%) were diagnosed with imaging and histologically
confirmed concurrent HCC at baseline. Six of them were catego-
rized at stage A, 4 at stage B, 12 at stage C and the rest 6 at stage D,
according to BCLC staging system, whereas half of HCC patients
(14/28, 50%), presented with portal vein thrombosis.
Overall, mean plasma FGL-2 levels were 4.04±3.80 pg/ml in the
whole cirrhotic population but were significantly higher in patients
with CP-B/C cirrhosis (6.07±4.80 pg/ml) compared to those with
CP-A liver disease (2.82±2.27 pg/ml, p<0.0001). Additionally,
mean plasma FGL-2 levels were significantly elevated in 28 cir-
rhotic patients with HCC at baseline (6.41±4.20 pg/ml) compared
to 84 cirrhotic patients without HCC (3.24±3.29 pg/ml, p=0.001).
Moreover, CP-B/C cirrhotic patients with HCC (n=18) exhibited
significantly higher FGL-2 levels (7.84±4.24 pg/ml) compared to
25 CP-B/C cirrhotic patients without HCC at baseline (4.87±5.20
pg/ml, p=0.024). Patients categorized at advanced and terminal
(BCLC-C/D) HCC stages (n=18) exhibited the highest plasma
FGL-2 levels (8.17±4.31 pg/ml) that were remarkably higher to
the corresponding ones of those of the earlier (BCLC-A/B) HCC
stages (3.53±2.20 pg/ml, p=0.008). It seems that the presence of
HCC as well as the stage of the disease according to BCLC sys-
tem (which includes the Child-Pugh score) significantly influences
plasma FGL-2 levels in cirrhotic patients.
Eighty-four cirrhotic patients (57 males) without HCC at base-
line control were followed-up from January 2015 until December
2020 according to the HCC surveillance program (liver ultrasound
and serum AFP levels every 6 months). Diabetes was present in
21 (25%) and esophageal varices in 41 (49%) of them. The main
cause of the underlying chronic liver disease was chronic hepatitis
C virus infection in 31/84 (37%) of cases, chronic hepatitis B virus
infection in 10/84 (12%) of cases, non-alcoholic and/or alcoholic
liver disease in 28/84 (33%) of cases and autoimmune liver disease
in 13/84 (15%) of them. The vast majority of cirrhotic patients
(59/84, 70%) were categorized as CP-A and the rest 25 (30%) as
CP-B/C (19 CP-B and 6 CP-C).
Fourteen patients (14/84, 16.6%) developed HCC during the
5-years follow-up period (HCC group) and 70 (83.3%) did not
(control group). HCC diagnosis was supported by compatible dy-
namic CT and MRI findings and was also histological confirmed
in all cases. Demographic and clinical data of the 14 patients who
developed HCC during surveillance as well as HCC stage at diag-
nosis were presented in table 1. As expected the majority of HCC
cases appeared in CP-B/C cirrhotic patients (9/14, 64%). Nine out
of 25 CP-B/C cirrhotic patients (36%) developed HCC during the
follow-up period in contrast to only 5/59 (8.5%) CP-A patients. It
is important to note that all five patients who were categorized as
CP-A cirrhotics at baseline and developed HCC during the sur-
veillance period were categorized in very early (BCLC-0, n=2) or
early (BCLC-A, n=3) HCC stage and were treated with potentially
curative procedures (2 with liver resection and 3 with radiofre-
quency ablation). Three of them were alive without HCC recur-
rence or liver disease deterioration at the end of follow-up and
the other 2 died from liver-related complications following HCC
recurrence. On the other hand the majority of cirrhotic patients
categorized at CP-B/C stage (6/9, 66.6%) at baseline were staged
at intermediate BCLC-B (n=3) or advanced BCLC-C (n=3) stage
4. Volume 5 Issue 3 -2021 Research Article
clinicsofoncology.com 4
at the time of HCC diagnosis and only 3 of them at early BCLC-A
stage. Only two of them are still alive (one following successful
orthotopic liver transplantation and one following locoregional
treatment, both at BCLC-A stage) whereas 7 have died from liver
related events and/or HCC progression during follow-up period.
Demographic, clinical and laboratory data among patients from the
HCC group and control group are presented in table 2. As we can
clearly see from this table patients age (p=0.60), gender (p=0.20),
etiology of chronic liver disease (p=0.90), presence of diabetes
(p=0.10) or varices (p=0.07) as well as MELD score were compa-
rable between the two groups. In the univariate analysis only the
Child-Pugh score (CP-B/C vs A, p=0.006) and the platelet count
(p=0.008) were significantly correlated with HCC appearance.
Patients from HCC group had significantly lower platelet count
(mean 98.700 vs 147.400, p=0.008) and were frequently catego-
rized at CP B/C stage (64.3% vs 22.9%, p=0.006) at baseline com-
pared to control group. Concerning plasma FGL-2 and serum AFP
levels at baseline, only FLG-2 levels (p=0.01) but not AFP levels
(p=0.15) significantly differed between the two groups of patients.
The median values of FGL-2 and AFP among patients from HCC
and control group were (3.6 pg/ml vs 2.1 pg/ml, p=0.01) and (6.0
ng/ml vs 4.0 ng/ml, p=0.15), respectively.
In order to evaluate the impact of liver disease severity in HCC
appearance as well as its influence on the levels of biomarkers we
continue a multivariate, logistic regression analysis taking into ac-
count patient age, gender, platelet count, Child-Pugh score, MELD
score as well as baseline FGL-2 and AFP levels as linear or dichot-
omous variable using the median values (3.6 pg/ml for FGL-2 and
6 ng/ml for AFP). In the multivariate logistic regression analysis,
only patients gender (OR=20.801, 95%CI: 1.504-287.7, p=0.024),
platelets (OR=0.980, 95%CI:0.964-0.997, p=0.025) and base-
line CP score (CP-B/C vs A, OR=27.184, 95%CI:2.815-262.5,
p=0.004) were significantly correlated with HCC appearance
during the follow-up period, as shown in table 3. In this analysis
plasma FGL-2 levels did not relate with HCC appearance either
using them as linear (OR=1.16, 95%CI:0.96-1.41, p=0.13) or as
dichotomous variable (OR=4.18, 95%CI:0.79-22.14, p=0.093) in
the multivariate model.
Table 1: Characteristics of 14 patients who developed HCC during surveillance
Age Gender Etiology ChildPugh score Meld score BCLC at HCC diagnosis
1 56 M HCV A5 7 0
2 55 M ALD A5 9 A
3 68 M HBV A5 10 A
4 68 M HCV B7 10 A
5 60 M HCV B7 13 C
6 76 M HCV A6 8 A
7 62 M HBV B7 8 B
8 74 M ALD C11 18 B
9 71 F PBC B8 8 C
10 78 M NAFLD A5 6 0
11 60 M ALD B7 13 B
12 60 F PBC B8 10 A
13 74 M ALD C13 19 C
14 70 M NAFLD B8 13 B
MELD score: Model For End-Stage Liver Disease, BCLC: Barcelona Clinic Liver Cancer, HCC : hepatocellular carcinoma,
HCV: hepatitis C virus, ALD: alcoholic liver disease, HBV: hepatitis B virus, PBC: primary biliary cholangitis, NAFLD:
nonalcoholic fatty liver disease
Table 2: Demographic, clinical and laboratory baseline data among cirrhotic patients under HCC surveillance
HCC
p-value
NO (n=70) YES (n=14)
Ν % Ν %
Gender 0.2a
Male 45 78.9 12 21.1
Female 25 92.6 2 7.4
Age b
63.5 11.2 65.1 6.9 0.6c
Cirrhosis Etiology 0.9
HCV 27 87.1 4 12.9
HBV 8 80 2 20
NASH/ALD 22 78.6 6 21.4
AH/PBC 11 84.6 2 15.4
CRYPTOGENIC 2 100 0 0
Diabetes 0.1a
No 55 87.3 8 12.7
Yes 15 71.4 6 28.6
5. Volume 5 Issue 3 -2021 Research Article
clinicsofoncology.com 5
Decompensation 0.001a
No 55 91.7 5 8.3
Yes 15 62.5 9 37.5
CTP Score 0.006d
A 54 91.5 5 8.5
B 12 63.2 7 36.8
C 4 66.7 2 33.3
Varices 0.07a
No 39 90.5 4 9.5
Yes 31 75.6 10 24.4
PLTsb
(K/μl) 147.4 62.6 98.7 51.1 0.008c
MELD scoreb
9.7 5 10.9 3.9 0.4c
FGL-2 0.01e
Median value (range) (pg/ml) 2.1 (18.4) 3.6 (16.7)
AFP 0.15e
Median value (range) (ng/ml) 4.0 (73.8) 6(126.0)
a
chi-square test b
mean, standard deviation c
independent samples t-test d
chi-square trend test e
Mann-Whitney test
HCC: hepatocellular carcinoma, HBV: hepatitis B virus, HCV: hepatitis C virus, NAFLD: non -alcoholic fatty liver disease, ALD: alcoholic liver
disease, AH: autoimmune hepatitis, PBC: primary biliary cholangitis, CTP score: ChildTurcotte-Pugh score, MELD score: Model For End-Stage
Liver Disease score, PLTs: platelets, FGL-2: fibrinogen like protein-2, AFP: a-fetoprotein
Table 3: Logistic Regression Analysis with HCC appearance as the dependent variable
Odds ratio 95% confidence interval p-value
PLTs 0.980 0.964 – 0.997 0.025
MELD 0.764 0.583 – 1.002 0.051
AGE 1.047 0.962 – 1.139 0.286
GENDER (Males
vs. females)
20.801 1.504 – 287.7 0.024
CTP B-C vs Α 27.184 2.815 – 262.5 0.004
FGL-2 2.834 0.497 – 16.15 0.241
AFP 5.455 0.878 – 33.87 0.069
CTP score: Child-Turcotte-Pugh score, MELD: Model For End-Stage Liver Disease, PLTs: platelets, FGL-2: fibrinogen like protein-2,
AFP: a-fetoprotein
5. Discussion
The vast majority of HCC cases occur in the setting of severe
chronic liver disease of any etiology and liver cirrhosis is the stron-
gest risk factor of HCC emergence [12]. The cirrhotic background
seems to play a crucial role in the development and progression of
HCC as chronic liver disease deranges hepatic immune tolerogen-
ic network facilitating tumor development [13]. Cytotoxic T Lym-
phocytes (CTLs) and Natural Killer (NK) cells are antitumor im-
mune cells that play an integral role in cancer immune surveillance
and eradication of tumor cells whereas accumulation of regulatory
T cells (Tregs) that frequently occurs in HCCs, is associated with
CTLs and NK cells dysfunction, tumor invasiveness as well as
progression, and poor patient outcomes [12, 13]. Fibrinogen-like
protein 2 (FGL-2), that is mainly secreted by regulatory T cells,
has been demonstrated to promote tumor progression by regulat-
ing cellular components of the tumor microenvironment [9, 13]. In
our study we evaluate soluble FGL-2 levels in Caucasian cirrhotic
patients with or without HCC as well as their predictive value for
HCC emergence during the surveillance program.
Our results are in accordance with other studies [8, 10] which con-
clude that liver disease severity is significantly related to plasma
FGL-2 levels. Patients with liver cirrhosis exhibited higher FGL-
2 levels compared to non-cirrhotics with chronic hepatitis C [8]
or chronic hepatitis B [10] but levels were comparable among
patients with HBV-related cirrhosis with or without HCC [10],
suggesting that mainly cirrhotic background significantly affects
them. Additionally, in a study with a small sample size, among 21
HCC patients, those with cirrhosis (n=10) exhibited significantly
higher levels of sFGL-2 compared to 11 non-cirrhotic individuals
[11]. In our study patients with advanced liver cirrhosis (Child-
Pugh stage B/C) with HCC exhibited significantly higher FGL-2
levels (7.84±4.24 pg/ml) compared to CP-B/C cirrhotic patients
without HCC (4.87±5.20 pg/ml, p=0.024) and patients at advanced
or terminal (BCLC-C/D) HCC stages exhibited the highest plasma
FGL-2 levels (8.17±4.31 pg/ml) that were remarkably higher to
the corresponding ones of those of earlier (BCLC-A/B) HCC stag-
es (3.53±2.20 pg/ml, p=0.008). It seems that the interaction of ad-
vanced liver disease with the high tumor burden and/or vascular in-
vasion observed in HCC cirrhotic patients of advanced (BCLC-C)
or terminal (BCLC-D) stage significantly affects plasma FGL-2
levels. It is important to note that portal vein thrombosis was ob-
served only in 14 cirrhotic patients with HCC at baseline control,
who by definition were categorized as advanced or terminal stage
(BCLC-C/D), so it was impossible to evaluate the specific impact
of this major event and its possible consequences (aggravation of
6. Volume 5 Issue 3 -2021 Research Article
clinicsofoncology.com 6
portal hypertension, bacterial translocation etc.) on FGL-2 levels.
Surveillance programs for hepatocellular carcinoma aim to detect
liver tumors at an early stage when they are amenable to potentially
curative therapy that is known to improve patient’s survival [14].
Based on HCC volume doublingtime? EASL/AASLD recommen-
dations support a 6-month screening interval, mainly with abdom-
inal ultrasound as the primary surveillance test recommended [3,
4].Although ultrasound has an acceptable sensitivity (84%) for de-
tecting HCC at any stage, its sensitivity for detection of early stage
HCC is significantly lower (47%) and did not always translate into
survival benefit [15]. The latter could be influenced by the cirrhot-
ic background of patients with HCC, as classical scores for liver
cirrhosis severity such as Child-Pugh score are taken into account
in BCLC staging of HCC and impact patients’ prognosis. In our
study, remarkable survival was observed only in CP-A cirrhotic
patients at baseline who finally developed HCC were categorized
at BCLC-0/A stage, so liver resection or locoregional therapies
with favorable outcome could be implemented. On the contrary
intermediate or advanced BCLC staging and poor clinical outcome
was noticed in the majority of CPB/C cirrhotic patients with HCC
emergence during the surveillance period. For these reasons most
clinical practice guidelines [3, 4, 5] did not suggest HCC screen-
ing in patients with decompensated cirrhosis (especially those of
ChildPugh C stage and/or MELD score above 20), unless they are
listed for liver transplantation, because they are unlikely to benefit
from HCC treatment. All patients with liver cirrhosis do not have
the same risk of developing HCC and it remains difficult to assess
the specific risk at an individual level [16]. In order to improve the
sensitivity for early HCC detection in cirrhotic patients, several
serum biomarkers (AFP, lectin-bound AFP, des-gamma carboxy
prothrombin etc.) as well as combinations of them with clinical
and routine laboratory data in panels (GALAD, BALAD-2) have
been evaluated [17].
Serum AFP levels exhibit poor sensitivity for early HCC detec-
tion, when used alone. At a cut-off value of 20 ng/mL, the most
commonly used cut-off value in clinical practice, AFP has a sen-
sitivity and specificity of approximately 60% and 80% for HCC,
respectively [18]. The accuracy of serum AFP levels for the de-
tection of HCC is limited especially in cirrhotic patients with
chronic HCV infection [18]. Concomitant use of liver ultrasound
and AFP improved the sensitivity of early HCC detection (63%)
compared to ultrasound alone (45%) [19]. Inclusion of serial AFP
measurements further improves the predictive value of HCC risk
in patients with HCV related cirrhosis. A model that incorporates
the rate of AFP change along with the most recent value of AFP
taking into account also patient age, serum alanine aminotrans-
ferase levels and platelet count is associated with improved sen-
sitivity for early HCC detection compared to the standard of care
surveillance program [20]. To our knowledge this study is the first
which tries to evaluate the predictive value of plasma FGL-2 levels
for HCC emergence among cirrhotic patients. It was hypothesized
that cirrhotic patients without HCC but with relatively elevated
FGL-2 levels could have created a potentially immunosuppressive
microenvironment that could facilitate tumor development in the
near future. Eighty-four cirrhotic patients, mainly with compen-
sated Child-Pugh A liver cirrhosis (70%), joined a 5-year follow-
up for HCC emergence. Baseline serum AFP levels did not differ
between the HCC group and the control group whereas there was
a significant difference between the two groups concerning plasma
FGL-2 levels. In the multivariate analysis, taking into account sev-
eral parameters that reflect liver failure and/or portal hypertension,
such as platelet count, MELD score and Child-Pugh score, the sta-
tistical significance of plasma FGL-2 levels was lost, suggesting
once again that liver disease severity probably influences them.
The higher levels of baseline FGL2 in patients who develop HCC
compared to ones who did not, could be explained by the obser-
vation that the majority of patients who finally developed HCC
(64%) were categorized in Child-Pugh B/C score. As expected
only male gender, Child-Pugh B/C score and low platelet count (as
an indirect marker of significant portal hypertension) could predict
HCC emergence.
Limitations of our study were the relative small sample size or
small number of patients, the mixed etiology of advanced liver
disease of patients, the relatively small proportion of those who
finally develop HCC, especially from the subgroup of cirrhotic
patients with compensated liver disease (Child-Pugh A5), as well
as the calculation of FGL-2 levels only at the baseline visit. Thus,
random error as indicating by wide confidence intervals in mul-
tivariate logistic regression model was unavoidable. This neces-
sitates the replication of the results in larger samples of cirrhotic
patients with long-term follow-up and recording of HCC events
as well as clinical outcomes. On the other hand this small pilot
study was performed in a single Hepatogastroenterology Unit of
a General and Oncology Hospital, with the same experts in Hepa-
tology, Gastroenterology, Liver imaging and Liver Histopathology
and all the measurements were done in the same laboratory, which
possibly reduces observer biases and somehow outweighs the lim-
itations of the study.
In conclusion, plasma FGL-2 levels are significantly elevated in
cirrhotic patients with decompensated liver disease compared to
those with compensated cirrhosis and presence of HCC as well as
HCC staging, according to the BCLC staging system, seems to sig-
nificantly further influence them. Liver disease severity, according
to Child-Pugh scoring system as well as low platelet count, but not
baseline plasma FGL-2 or serum AFP levels, could predict HCC
emergence among Caucasian cirrhotic patients.
7. Volume 5 Issue 3 -2021 Research Article
clinicsofoncology.com 7
References
1. McGlyn KA, Petrick JL, El Serag HB. Epidemiology of hepatocellu-
lar carcinoma. Hepatology. 2021; 73(S1): 4-13.
2. Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019; 380:
1450-62.
3. EASL Clinical Practice Guidelines: Management of hepatocellular
carcinoma. J Hepatol. 2018; 69: 182-236.
4. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM,
et al. Diagnosis, Staging and Management of hepatocellular carci-
noma: 2018 Practice Guidance by the American Association for the
Study of Liver Diseases. Hepatology. 2018; 68(2): 723-50
5. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J et al.
AsiaPacific clinical practice guidelines on the management of hepa-
tocellular carcinoma: a 2017 update. Hepatol Int. 2017; 11: 317-70.
6. Eggert T, Greten TF. Tumor regulation of the tissue environment in
the liver. Pharmacol Ther. 2017; 173: 47-57.
7. Tesi RJ. MDSC: the most important cell you have never heard of.
Trends Pharmacol Sci. 2019; 40: 4-7.
8. Foerster K, Helmy A, Zhu Y, Khattar R, Adeyi OA, Wong KM et al.
The novel immunoregulatory molecule FGL2: A potential biomarker
for severity of chronic hepatitis C virus infection. J Hepatol. 2010;
53: 608-15.
9. Liu BQ, Bao ZY, Zhu JY, Liu H. Fibrinogen-like protein-2 promotes
the accumulation of myeloid-derived suppressor cells in the hepa-
tocellular carcinoma tumor microenvironment. Oncol Lett. 2021;
21(1): 47.
10. Van Tong H, Van Ba N, Xuan Hoan N, Thanh Binh M, Thanh Quyen
D, Anh Son H, et al. Soluble fibrinogen-like protein-2 levels in pa-
tients with hepatitis B virus related liver diseases. BMC Infectious
Diseases. 2018; 18: 553.
11. Sun Y, Xi D, Ding W, Wang F, Zhou H, Ning Q. Soluble FGL2, a
novel effector molecule of activated hepatic stellate cells, regulates
T-cell function in cirrhotic patients with hepatocellular carcinoma.
Hepatol Int. 2014; 8: 567-75.
12. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E,
Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers.
2021; 7(1): 6.
13. Risvi S, Wang J, El-Khoueiry AB. Liver Cancer Immunity. Hepatol-
ogy. 2021; 73(S1): 86-103.
14. Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance
for hepatocellular carcinoma: New trendsJ Hepatol. 2020; 72: 250-
61.
15. Moon AM, Weiss NS, Beste LA, Su F, Ho SB, Jin GY, et al. No asso-
ciation between screening for hepatocellular carcinoma and reduced
cancer-related mortality in patients with cirrhosis. Gastroenterology.
2018; 155: 1128-39.
16. Goldberg DS, Taddei TH, Serper M, Mehta R, Dieperink E, Aytaman
A, et al. Identifying barriers of hepatocellular carcinoma surveillance
in a national sample of patients with cirrhosis. Hepatology. 2017;
65(3): 864-74.
17. Berhane S, Toyoda H, Tada T, Kumada T, Kagebayashi C, Satomura
S et al. Role of the GALAD and BALAD-2 serologic models in
diagnosis of hepatocellular carcinoma and prediction of survival in
patients. Clin Gastroenterol Hepatol. 2016; 14: 875-86.
18. Gopal P, Yopp AC, Waljee AK, Chiang J, Nehra M, Kandunoori P,
et al. Factors that affect accuracy of a-fetoprotein test in detection of
hepatocellular carcinoma in patients with cirrhosis. Clin Gastroen-
terol Hepatol. 2014; 12(5): 870-7.
19. Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, et
al. Surveillance imaging and a-fetoprotein for early detection of
hepatocellular carcinoma in patient with cirrhosis: a meta-analysis.
Gastroenterology. 2018; 154: 1706-18.
20. White DL, Richardson P, Tayoub N, Davila JA, Kanwal F, El-Serag
HB. The updated model: an adjusted serum alpha-fetoprotein based
algorithm for hepatocellular carcinoma detection with hepatitis C
virus related cirrhosis. Gastroenterology. 2015; 149: 1986-7.